BSECompany UpdateResults1d ago
Orchid Pharma Ltd
Audio Recording of the Analysts/Investors Earnings Call - Orchid Pharma Limited ('the Company')
Orchid Pharma Ltd has uploaded the audio recording of its Analysts/Investors Earnings Call on its website, discussing unaudited limited reviewed financial results for Q2 FY 2026-27.
BSECompany UpdateResults2d ago
Orchid Pharma Ltd
Board Comments on fine levied by Stock Exchanges
Orchid Pharma Ltd has been fined Rs. 2000 each by National Stock Exchange of India Limited and BSE Limited for a one-day delay in filing its annual report. The company's board has taken note of the payment of fines and advised the management to strengthen its internal compliance monitoring mechanism.
BSECompany Update▲ PositiveResults2d ago
Orchid Pharma Ltd
Investor Presentation-Quarter II of FY 2026-27, ended on September 30, 2026
Orchid Pharma Ltd has released its Investor Presentation for Q2 FY 2026-27, showcasing its financial performance and business prospects. The company has made significant progress in its anti-infectives business, with a strong presence in regulated markets and a focus on long-term growth.
BSECompany UpdateResults4d ago
Orchid Pharma Ltd
Statement of deviation or variation for the quarter ended on September 30, 2026 on the use of proceeds of funds raised through Qualified institutional placement (QIP)
Orchid Pharma Ltd has filed a statement of deviation or variation for the quarter ended September 30, 2026, on the use of proceeds of funds raised through Qualified Institutional Placement (QIP). The company has reallocated the QIP proceeds from the API Facility in Alathur to other projects, citing changes in the business environment and strategic requirements.
BSEResult▼ NegativeResults4d ago
Orchid Pharma Ltd
Declaration of Financial results for quarter and half year ended on September 30, 2026
Orchid Pharma Ltd has declared its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The company's net sales income for the quarter stood at ₹34,126.66 lakhs, a decrease of 14.5% from the same period last year. The company's profit before tax for the quarter was ₹2,683.69 lakhs, a decrease of 27.5% from the same period last year.
BSEBoard MeetingResults4d ago
Orchid Pharma Ltd
Outcome of Board Meeting
Orchid Pharma Ltd's board meeting outcome announced unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The company reported a net sales income of ₹34,126.66 crore and ₹64,543.79 crore for the quarter and half year respectively. Profit before tax stood at ₹3,675.93 crore and ₹4,869.65 crore for the quarter and half year respectively.
BSECompany UpdateResults6d ago
Orchid Pharma Ltd
Intimation of schedule of Analysts/ Investors Earning Call for the Ouarter-II of F.Y. 2026-27 ended on September 30, 2026
Orchid Pharma Ltd has announced the schedule of Analysts/Investors Earning Call for the Quarter-II of F.Y. 2026-27 ended on September 30, 2026, to be held on November 17, 2026, at 4:30 P.M. to discuss the financial performance/financial results of the Company.
BSEBoard MeetingResults11 Nov 2026
Orchid Pharma Ltd
Orchid Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve Unaudited Limited Reviewed Financial Results (Standalone & Consolidated) of the Company for the Quarter-II and half year ended on September 30, 2026.
Orchid Pharma Ltd has informed BSE that the meeting of the Board of Directors is scheduled on November 14, 2026, to consider and approve Unaudited Limited Reviewed Financial Results for the Quarter-II and half year ended on September 30, 2026.
BSECompany Update▲ PositiveOrder Win24 Oct 2026
Orchid Pharma Ltd
Announcement under regulation 30 regarding the licensing and supply agreement with Laboratorio Libra S.A.
Orchid Pharma Ltd has entered into a licensing and supply agreement with Laboratorio Libra S.A. for Exblifep (Cefepime/Enmetazobactam) in nine Latin American markets, with a potential commercial opportunity of approximately USD 80 million over the first 10 years.
BSECompany UpdateFundraise20 Oct 2026
Orchid Pharma Ltd
Outcome of Board Meeting for Raising Funds ("Enabling Resolution")
Orchid Pharma Ltd's board has approved a proposal to raise up to Rs. 600 Crores through the issue of equity shares or other eligible securities, including convertible debentures, through various modes such as QIP, private placement, or public issue.
BSEBoard Meeting▲ PositiveFundraise20 Oct 2026
Orchid Pharma Ltd
Outcome of Board Meeting
Orchid Pharma Ltd's board meeting outcome reveals the company's intention to explore potential market opportunities for raising funds through the issue of equity shares or other eligible securities, up to Rs. 600 Crores.
BSEBoard MeetingFundraise15 Oct 2026
Orchid Pharma Ltd
Orchid Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/10/2026 ,inter alia, to consider and approve Prior intimation of Board Meeting scheduled to be held on October 20, 2026, inter alia to consider and approve enabling resolution for raising of funds
Orchid Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/10/2026 to consider and approve enabling resolution for raising of funds.
BSECompany UpdateRegulatory9 Oct 2026
Orchid Pharma Ltd
Certificate under Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulation, 2018
Orchid Pharma Ltd has issued a certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, confirming the compliances required under the above said regulation for the Quarter-II of Financial Year 2026-27 ended on September 30, 2026.
BSEAGM/EGM3 Oct 2026
Orchid Pharma Ltd
Scrutinizer''s Report and Voting Result-33rd Annual General Meeting of Orchid Pharma Limited
Orchid Pharma Ltd has announced the Scrutinizer's Report and Voting Results for its 33rd Annual General Meeting held on September 29, 2026, through Video Conferencing (VC) or Other Audio-Visual Means (OAVM). The meeting was conducted in accordance with the Companies Act, 2013, and SEBI (LODR) Regulations 2015.
BSEAGM/EGM29 Sept 2026
Orchid Pharma Ltd
Proceedings of 33rd Annual General Meeting of Orchid Pharma Limited Held on 29th September 2026
Orchid Pharma Ltd held its 33rd Annual General Meeting on September 29, 2026, through video conferencing, with 32 members present. The meeting was chaired by Manish Dhanuka, Managing Director, after Ram Gopal Agarwal's absence. The company secretary informed the members about the auditors' report, which did not contain any qualification, but had certain qualifications in the consolidated auditor's report.
BSEInsider Trading / SASTResults28 Sept 2026
Orchid Pharma Ltd
Intimation of Trading Window closure for Quarter-II of Financial Year 2026-27, ending on September 30, 2026.
Orchid Pharma Ltd has announced the closure of its trading window for the quarter ending September 30, 2026, due to the upcoming declaration of unaudited financial results.
BSECompany UpdateM&A23 Sept 2026
Orchid Pharma Ltd
Intimation under regulation 30- Trading Approval of Equity Shares issued and allotted under Scheme of Amalgamation
Orchid Pharma Ltd has informed about the trading approval of equity shares issued and allotted under the Scheme of Amalgamation, which have been listed and admitted to dealings on NSE and BSE with effect from September 23, 2026.
BSECompany UpdateRegulatory22 Sept 2026
Orchid Pharma Ltd
Intimation under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015
Orchid Pharma Ltd has purchased a land situated at Patibulum Village, Kancheepuram District, Tamil Nadu, marking the permanent closure of the company's arrangement with DBS Bank India Limited in relation to the said property.
BSEGeneralResults8 Sept 2026
Orchid Pharma Ltd
Annual Report of the Company for FY 2025-26.
Orchid Pharma Ltd has announced its Annual Report for FY 2025-26, along with the Notice of 33rd Annual General Meeting scheduled for September 29, 2026.
BSEAGM/EGM7 Sept 2026
Orchid Pharma Ltd
Notice of 33rd Annual General Meeting of the Company
Orchid Pharma Ltd has announced the notice of its 33rd Annual General Meeting for the financial year 2025-26.